

IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

---

IN RE: GENERIC PHARMACEUTICALS  
PRICING ANTITRUST LITIGATION

---

MDL 2724  
16-MD-2724

THIS DOCUMENT RELATES TO:

*State Attorneys General Litigation*

---

HON. CYNTHIA M. RUFÉ

Civil Action No.  
17-3768

**DEFENDANT ASCEND LABORATORIES, LLC'S  
RULE 7.1 CORPORATE DISCLOSURE STATEMENT**

Pursuant to Federal Rule of Civil Procedure 7.1, Defendant Ascend Laboratories, LLC, hereby states that it is a wholly-owned subsidiary of Alkem Laboratories Ltd., which is a publicly-traded company. Alkem Laboratories Ltd. is the only publicly-traded company that owns 10% or more of the stock of Ascend Laboratories, LLC.

Dated: August 14, 2018

Respectfully submitted,

/s/ W. Gordon Dobie

W. Gordon Dobie  
WINSTON & STRAWN LLP  
35 W. Wacker Dr.  
Chicago, IL 60601  
Tel: (312) 558-5600  
Fax: (312) 558-5700  
WDobie@winston.com

*Counsel for Defendant Ascend  
Laboratories, LLC*

/s/ Irving Wiesen

Irving Wiesen  
LAW OFFICES OF IRVING L. WIESEN, P.C.  
420 Lexington Avenue - Suite 2400  
New York, New York 10170  
Tel: (212) 381-8774  
Fax: (646) 536-3185  
IWiesen@wiesenlaw.com  
(Appearance forthcoming)

*Counsel for Defendant Ascend Laboratories,  
LLC*

**CERTIFICATE OF SERVICE**

I, W. Gordon Dobie, hereby certify that a true and correct copy of the foregoing Rule 7.1 Corporate Disclosure Statement was served on all counsel of record via ECF on August 14, 2018. Pursuant to Local Rule 5.1.2(8)(b), I further certify that the foregoing document is available for viewing and downloading on ECF.

Dated: August 14, 2018

/s/ W. Gordon Dobie  
W. Gordon Dobie